Research Associate FirmaLab Los Angeles, California, United States
Abstract Text: As of January 2022, it is estimated that over 60 million individuals have been infected by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the United States, and over 300 million individuals worldwide[1]. These staggering numbers have burdened physicians and scientists with the monstrous task of treating infected patients whose symptoms range in severity from asymptomatic to life-threatening, while concurrently investigating the novel disease’s biology and immune responses to infection and vaccination. While emerging literature has helped illuminate aspects of physiological immune responses to coronavirus disease 19 (COVID-19), the relationship between symptom severity and humoral immune response remains poorly understood. Additionally, the impact of this variability on the development of protective immune responses and the role of antibodies in disease is unclear, which has raised questions on the difference between neutralizing antibodies in those vaccinated and those unvaccinated. Our study aims to explore neutralizing antibody presentation against COVID-19 in groups of individuals with different histories of SARS-CoV-2 exposure and vaccination status. Thus, our findings will help further the understanding of humoral immunity as it relates to COVID-19.
Conclusion: There is a relation between total antibodies and neutralizing antibodies in people with various COVID histories.
